The PMHNP is treating a 76-year-old woman with an atypical antipsychotic who is exhibiting extrapyramidal symptoms (EPS). The PMHNP understands that for EPS symptoms to decrease, which neurotransmitter must be decreased?

Choice A reason: Dopamine plays a central role in the pathophysiology of extrapyramidal symptoms. EPS occurs due to dopamine receptor blockade in the nigrostriatal pathway, particularly with antipsychotic medications. Reducing dopamine activity in this pathway leads to motor disturbances similar to Parkinsonism. Therefore, managing EPS often involves balancing dopamine levels or using medications that counteract dopamine blockade. Choice B reason: Serotonin is involved in mood regulation and other central nervous system functions, but it is not directly implicated in the development of EPS. While some antipsychotics affect serotonin receptors, EPS symptoms are primarily linked to dopamine dysregulation. Choice C reason: Norepinephrine is associated with arousal, attention, and stress responses. It does not play a significant role in the extrapyramidal system, and altering its levels would not directly alleviate EPS. Choice D reason: Glutamate is the primary excitatory neurotransmitter and is involved in learning and memory. Although it interacts with dopamine systems, it is not the primary neurotransmitter responsible for EPS, and decreasing glutamate would not be a targeted approach for treating these symptoms.